BioStock Studio: Scandion Oncology brings in New CEO

Name: BioStock Studio: Scandion Oncology brings in New CEO
Uploaded: 2021-07-04T11:54:16+02:00
Channel: Johan Hilding
Description: Scandion Oncology’s top candidate, SCO-101, is currently in a phase II clinical trial with metastatic colorectal cancer patients. As the study progresses, the company is beginning a new phase in its development program. In light of this, the company has appointed Bo Rode Hansen as CEO, while former CEO Nils Brünner takes the role as

Home Interviews BioStock Studio: Scandion Oncology brings in New CEO

BioStock Studio: Scandion Oncology brings in New CEO

4 July, 2021

BioStock Studio: Scandion Oncology brings in New CEO

4 July, 2021

Scandion Oncology’s top candidate, SCO-101, is currently in a phase II clinical trial with metastatic colorectal cancer patients. As the study progresses, the company is beginning a new phase in its development program. In light of this, the company has appointed Bo Rode Hansen as CEO, while former CEO Nils Brünner takes the role as CSO, to strengthen its executive leadership. Both Rode Hansen and Brünner came to the BioStock studio to discuss the change.Watch the full interview with Scandion Oncology’s CEO Bo Rode Hansen and CSO Nils Brünner below.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev

RELATED ARTICLESMORE FROM AUTHOR

Stockholm’s five top and bottom life science shares in Q1

Positive outcome for Alligator Bioscience’s joint study with Scandion Oncology

Key advancements for Alligator Bioscience in Q2

RELATED ARTICLES MORE FROM AUTHOR